Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Xencor, Inc. XNCR

Healthcare  —  Biotechnology
23.80 (0.08) (0.34%) as of 25 Sep
Market cap
$1.8B
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Xencor, Inc. (XNCR) Business Profile

Updated before January 2025

Company Overview

Xencor, Inc. (NASDAQ: XNCR) is a clinical-stage biopharmaceutical company specializing in the development of engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Founded in 1997 and headquartered in Monrovia, California, Xencor has established itself as a leader in protein engineering, leveraging its proprietary XmAb® technology platform to create innovative therapies. The company’s leadership team includes key figures such as Bassil Dahiyat, Ph.D., who serves as President and Chief Executive Officer, and John Kuch, Chief Financial Officer. With a strong focus on research and development, Xencor has built a robust pipeline of drug candidates and forged strategic partnerships with leading pharmaceutical companies.

Core Business Segments

Xencor operates primarily in the biopharmaceutical sector, with a focus on developing therapies for oncology and autoimmune diseases. Its core business segments include:

1. Oncology

Xencor’s oncology portfolio is centered around engineered antibodies designed to enhance immune system responses against cancer cells. Key products in this segment include:

  • Plamotamab (CD20 x CD3 bispecific antibody): A bispecific antibody targeting B-cell malignancies.
  • XmAb® IL-15: A cytokine designed to activate natural killer (NK) cells and T cells for cancer immunotherapy.
  • XmAb® 819: A bispecific antibody targeting ENPP3 for renal cell carcinoma.

2. Autoimmune Diseases

Xencor is also developing therapies to address autoimmune and inflammatory diseases. Notable products include:

  • Vibecotamab (CD123 x CD3 bispecific antibody): Designed for the treatment of acute myeloid leukemia (AML).
  • XmAb®5871: A monoclonal antibody targeting autoimmune diseases by modulating B-cell activity.

3. Partnerships and Licensing

Xencor has licensed its XmAb® technology to several pharmaceutical companies, enabling the development of additional therapies. Partners include Novartis, Amgen, and MorphoSys, among others. These collaborations generate significant revenue through milestone payments and royalties.

Business Model

Xencor’s business model revolves around leveraging its XmAb® technology platform to create innovative therapies and generate revenue through a combination of product sales, licensing agreements, and strategic partnerships. The company invests heavily in research and development to advance its pipeline of drug candidates. Additionally, Xencor’s licensing agreements allow it to monetize its technology while sharing development risks with partners. This hybrid approach enables the company to maintain a steady revenue stream while focusing on long-term growth.

Strategic Direction

Xencor’s strategic direction is focused on expanding its pipeline of drug candidates, advancing clinical trials, and exploring new therapeutic areas. Key priorities include:

  • Pipeline Expansion: Xencor aims to develop additional bispecific antibodies and cytokines to address unmet medical needs in oncology and autoimmune diseases.
  • Global Partnerships: The company plans to strengthen its collaborations with pharmaceutical companies to accelerate the development and commercialization of its therapies.
  • Sustainability Goals: Xencor is committed to minimizing its environmental impact by adopting sustainable practices in its operations and supply chain.
  • New Product Categories: The company is exploring the potential of its XmAb® platform to create therapies for other indications, such as infectious diseases and neurological disorders.

Competitive Landscape

Xencor operates in a highly competitive biopharmaceutical market, facing competition from both established companies and emerging players. Key competitors include:

  • Regeneron Pharmaceuticals: Known for its innovative antibody-based therapies.
  • Amgen: A leader in oncology and autoimmune disease treatments.
  • Genmab: Specializes in antibody therapeutics, including bispecific antibodies.
  • MacroGenics: Focuses on developing bispecific antibodies for cancer treatment.

Despite the competition, Xencor’s proprietary XmAb® technology platform gives it a competitive edge by enabling the development of highly differentiated therapies.

Risk Factors

Xencor faces several risks that could impact its business operations and financial performance, including:

  • Regulatory Risks: The company’s drug candidates must undergo rigorous clinical trials and regulatory approvals, which are time-consuming and costly.
  • Market Dependence: Xencor relies heavily on the success of its lead drug candidates and licensing agreements for revenue generation.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply chain for raw materials and manufacturing.
  • Competition: Intense competition in the biopharmaceutical sector could limit Xencor’s market share and profitability.
  • Financial Risks: As a clinical-stage company, Xencor is not yet profitable and depends on external funding to finance its operations.

Recent Developments

Xencor has made significant progress in advancing its pipeline and expanding its partnerships. Recent developments include:

  • Clinical Trials: The company has initiated Phase 1 and Phase 2 clinical trials for several drug candidates, including Plamotamab and XmAb® IL-15.
  • Partnerships: Xencor recently announced a collaboration with Janssen Biotech to develop bispecific antibodies for oncology.
  • Corporate Strategy: The company has outlined plans to increase its investment in research and development to accelerate the discovery of new therapies.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of biopharmaceutical innovation, creating new opportunities for Xencor to address emerging healthcare challenges.

Investment Considerations

Investors considering Xencor should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Xencor’s XmAb® platform provides a competitive advantage in developing differentiated therapies.
  • Robust Pipeline: The company has a diverse portfolio of drug candidates targeting high-value markets.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies generate revenue and reduce development risks.

Risks

  • Clinical and Regulatory Risks: The success of Xencor’s drug candidates depends on the outcomes of clinical trials and regulatory approvals.
  • Financial Uncertainty: As a clinical-stage company, Xencor is not yet profitable and may require additional funding.
  • Market Competition: Intense competition could limit the company’s market share and revenue potential.

Conclusion

Xencor, Inc. is a pioneering biopharmaceutical company with a strong focus on developing innovative therapies for cancer and autoimmune diseases. Leveraging its proprietary XmAb® technology platform, the company has built a robust pipeline of drug candidates and established strategic partnerships with leading pharmaceutical companies. While Xencor faces significant risks, including regulatory challenges and market competition, its innovative approach and commitment to research and development position it well for future growth. As the company advances its pipeline and explores new therapeutic areas, it remains a compelling investment opportunity in the biopharmaceutical sector.